Last reviewed · How we verify
Atlantic Health System — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bupivacaine Hydrochloride and Lidocaine | Bupivacaine Hydrochloride and Lidocaine | marketed | ||||
| Lidocaine gel 2% | Lidocaine gel 2% | marketed | Local anesthetic | Voltage-gated sodium channels | Anesthesia/Pain Management | |
| Intravesical antibiotic instillation | Intravesical antibiotic instillation | marketed | Antibiotic instillation therapy | Urology / Infectious Disease | ||
| Antibiotic oral suppressive therapy | Antibiotic oral suppressive therapy | marketed | Antibiotic (suppressive therapy) | Infectious Disease |
Therapeutic area mix
- Anesthesia/Pain Management · 1
- Infectious Disease · 1
- Urology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams Maternity Hospital · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Aligarh Muslim University · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- B.P. Koirala Institute of Health Sciences · 1 shared drug class
- Bagcilar Training and Research Hospital · 1 shared drug class
- Bayero University Kano, Nigeria · 1 shared drug class
- Abant Izzet Baysal University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Atlantic Health System:
- Atlantic Health System pipeline updates — RSS
- Atlantic Health System pipeline updates — Atom
- Atlantic Health System pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Atlantic Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/atlantic-health-system. Accessed 2026-05-17.